ClinicalTrials.gg
Not yet recruitingNCT07407634Updated Feb 12, 2026

A Randomized, Double-blind, Single-center Phase I/IIa Study of XTYW007 Tablets in Subjects.

An Early Phase 1 interventional study of Test drug XTYW007 capsules and placebo,Single dose group and Test drug XTYW007 capsules and placebo,Food Impact Group in Non-Alcoholic Fatty Liver Disease, sponsored by Xi'an Xintong Pharmaceutical Research Co.,Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-02-12.

Sponsored by Xi'an Xintong Pharmaceutical Research Co.,Ltd. · Early Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Early Phase 1
Study type
Interventional
Enrollment
94
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China — 42 open to participants now, 53 under way, 5 of them phase 3. Non-alcoholic Fatty Liver Disease · China.

Planned enrollment
52nd of 89
94 · median 112
Started
2026
with 7 others
Phase 1
18 of 143
4 open now
Primary completion
2027-02
later than 32 of 52 live
Registered
136th of 143
by date

Among the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, this one is the 52nd largest by planned enrollment of the 89 interventional ones that give a count, is one of 8 that started in 2026, is one of 18 in phase 1, reaches primary completion later than 32 of the 52 other live ones, and was the 136th registered.

Non-alcoholic Fatty Liver Disease

1,618 studies on the registry are indexed under Non-alcoholic Fatty Liver Disease; 322 are open to participants now.

Browse Non-alcoholic Fatty Liver Disease studies →

Open to participants now

42 of the 143 studies in Non-alcoholic Fatty Liver Disease with a site in China are open now. Recruiting first, the newest first:

37 more — sign in →

All 42 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 219 Non-alcoholic Fatty Liver Disease studies recruiting now, 66 (30%) set no upper age limit and 124 (57%) stop at 75 or younger; 27 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 143 studies in Non-alcoholic Fatty Liver Disease with a site in China, or all of them as a file.
02

Study summary

Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.

Read the detailed description

This study is a single-center, randomized, double-blind Phase I/IIa clinical trial assessing the safety, tolerability, and pharmacokinetics of single and multiple doses.Aimed at evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of XTYW007 in healthy subjects and healthy subjects with elevated LDL-C, as well as studying the effects of food on the pharmacokinetics and metabolic transformation of XTYW007, and preliminarily assessing the pharmacodynamics of XTYW007.

03

Conditions studied

  • Non-Alcoholic Fatty Liver Disease
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects voluntarily sign the before the trial, and fully understand the content, process and possible adverse effects of the trial;
  2. They are able to complete the study according to the requirements of the trial protocol;
  3. Subjects (including partners) are willing to have no pregnancy plan and voluntarily use effective measures within 6 months from screening to the last dose of study drug;
  4. Male and female subjects between the ages of 18 and 65 (including borderline values);
  5. Male subjects weighing not less than 50 kg and female subjects weighing not less than 45 kg. (BMI) = weight (kg)/ height 2 (m2), BMI within the range of 18-28 kg/m2 (including the threshold value);
  6. During screening, for single-dose studies, fasting low-density lipoprotein cholesterol (LDL-C): 80 mg/dL \< LDL-C \< 120 mg/dL (2.06 mmol/L \~ 3.1 mmol/L); for multiple-dose studies, fasting low-density lipoprotein cholesterol (LDL-C) > 110 mg/dL (2.85 mmol/L);
  7. Physical examination and vital signs are normal or abnormal without clinical significance.

Exclusion criteria

Exclusion Criteria:

  1. Individuals with allergic constitution (allergic to multiple drugs and foods) or intolerance to β-blockers;
  2. History of thyroid-related diseases and/or thyroid function abnormalities during the screening phase that are ;
  3. Individuals who smoked more than 5 cigarettes per day in the 3 months prior to the trial;
  4. History of drug abuse and/or alcoholism (consuming 14 units of alcohol per week: 1 unit = 285 mL beer, 25 mL spirits, or 100 mL wine);
  5. Blood donation or significant blood loss (>450 mL) within 3 months prior to taking the study drug;
  6. Use of any prescription drugs, over-the-counter drugs, vitamins, herbal products, or alcohol within 14 days before taking the study drug;
  7. Consumption of special foods (such as grapefruit, mango, dragon fruit, grape juice, orange juice, etc., rich in flavonoids or coumarins) within 2 weeks before taking the study drug, or engaging in intense exercise, or other factors affecting drug absorption, distribution, metabolism, or excretion;
  8. Significant changes in diet or exercise habits recently;
  9. Use of the study drug or participation in a drug clinical trial within 3 months before taking the study drug;
  10. Difficulty swallowing or any gastrointestinal diseases affecting drug absorption within 6 months prior to the study;
  11. Any disease that increases bleeding risk, such as hemorrhoids, acute gastritis, or gastroduodenal ulcer;
  12. Clinically significant abnormalities; > 470 ms (QTcF = QT/(RR)\^0.33);
  13. Female subjects who are breastfeeding during the screening or trial phase, planning pregnancy in the near future, or have positive serum pregnancy results;
  14. Abnormal clinical laboratory test results with clinical significance, or other clinical findings within 12 months prior to screening that are clinically significant, including but not limited to diseases of the gastrointestinal tract, kidney, liver, nervous system, hematopoietic system, endocrine system, tumors, lungs, immune system, mental health, or cardiovascular and cerebrovascular systems;
  15. Any positive result for surface antigen, antibody/core antigen, antigen/antibody, or syphilis treponema antibody during screening;
  16. Occurrence of acute illness or concomitant medication use from the screening phase to the start of study medication;
  17. Consumption of chocolate, any caffeine-containing or xanthine-containing foods or beverages within 24 hours before taking the study drug;
  18. Serum ≤ 70 mL/min [calculation formula: Ccr: (140 - age) × weight (kg) / (0.818 × Scr) (μmol/L), ×0.85 for females];
  19. Subjects with special dietary requirements who cannot consume the complete study meal or who do not agree to adhere to water intake regimen and position restrictions during the trial;
  20. Subjects whom the investigator considers to have other factors that make them unsuitable for participation in this trial.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Early Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
94 participants (estimated)

Study arms

  • Experimental
    Single dose group

    Group 1 (0.2 mg), Group 2 (0.6 mg), Group 3 (1.5 mg), Group 4 (3 mg), Group 5, Group A (6 mg), Group 6 (10 mg), Group 7 (15 mg), optional dose Group 8 (20 mg)

    Drug: Test drug XTYW007 capsules and placebo,Single dose group

  • Experimental
    Food Impact Group

    Group 5, Subgroup A(6mg), Group 5, Subgroup B( 6 mg)

    Drug: Test drug XTYW007 capsules and placebo,Food Impact Group

  • Experimental
    Multiple dosing group

    Group 9 (1.5 mg), Group 10 (6 mg), Group 11 (15 mg)

    Drug: Test drug XTYW007 capsules and placebo,Multiple dosing group

Interventions

  • DrugTest drug XTYW007 capsules and placebo,Single dose group

    Each group consists of 8 people, with 6 receiving the trial drug XTYW007 and 2 receiving a placebo. The sentinel method is used for enrollment, meaning that the first 2 subjects (one male and one female, both receiving the trial drug) are enrolled and observed for 96 hours (after the Day 5 tolerance assessment). If there are no intolerable reactions, the remaining 6 subjects are enrolled and randomly assigned to receive the trial drug or placebo in a 2:1 ratio.

  • DrugTest drug XTYW007 capsules and placebo,Food Impact Group

    A two-period crossover administration was used, with a 14-day washout period. In Group A, 8 subjects received the drug on D1 under fasting conditions in the first period, and on D15 under fed conditions in the second period. In Group B, 6 subjects taking the investigational drug received it on D1 under fed conditions in the first period, and on D15 under fasting conditions in the second period.

  • DrugTest drug XTYW007 capsules and placebo,Multiple dosing group

    Each group consists of 8 subjects, with 6 receiving the investigational drug XTYW007 and 2 receiving a placebo. A sentinel dosing approach is used, where 2 subjects (one male and one female) are first enrolled and administered the investigational drug. After 96 hours of observation (tolerance evaluation on Day 5), if no intolerable issues occur, the remaining 6 subjects are enrolled and randomized 2:1 to receive the investigational drug or placebo. In the multiple-dose group, the drug is administered once every morning on an empty stomach (QD) for 14 consecutive days.

06

What researchers measure

Primary outcomes

  1. Treatment-related adverse events

    Number of participants who experienced treatment-related adverse events as assessed by CTCAE v5.0.

    Time frame: Days 1-11 of administration

  2. Cmax

    Cmax

    Time frame: Days 1-11 of administration

  3. Tmax

    Tmax

    Time frame: Days 1-11 of administration

  4. t1/2

    t1/2

    Time frame: Days 1-11 of administration

  5. AUC

    AUC

    Time frame: Days 1-11 of administration

  6. CL/F

    CL/F

    Time frame: Days 1-11 of administration

  7. Vz/F

    Vz/F

    Time frame: Days 1-11 of administration

  8. CLr/F

    CLr/F

    Time frame: Days 1-11 of administration

Secondary outcomes

  1. Ae0-72 h

    Ae0-72 h

    Time frame: Days 1-4 of administration

  2. Fe0-72 h

    Fe0-72 h

    Time frame: Days 1-4 of administration

  3. Blood lipids

    TC , TG , LDL-C, HDL-C, Apo A1, Apo B, Lp(a)

    Time frame: Days 1-11 of administration

  4. Thyroid function

    TSH, TT4, TT3, FT4, FT3

    Time frame: Days 1-11 of administration

  5. Sex hormone-binding globulin (SHBG)

    SHBG

    Time frame: Days 1-11 of administration

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Mar 2026; primary completion for Feb 2027, 11 months later.

Of 125 phase 1 interventional studies under Non-alcoholic Fatty Liver Disease, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 21. This study's planned 11 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2026
First posted
Feb 12, 2026
StartEst.
Mar 25, 2026
Primary completionEst.
Feb 26, 2027
CompletionEst.
May 27, 2027
Last update
Feb 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 12, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07407634
Lead sponsor
Xi'an Xintong Pharmaceutical Research Co.,Ltd.
Responsible party
Sponsor
First posted
Feb 12, 2026
Start date
Mar 25, 2026 (estimated)
Primary completion
Feb 26, 2027 (estimated)
Completion
May 27, 2027 (estimated)
Last update
Feb 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion